Orexo (ORX) Aandelenoverzicht
Orexo AB (publ), een gespecialiseerd farmaceutisch bedrijf, ontwikkelt en verkoopt geneesmiddelen en digitale therapieën in de Verenigde Staten, de Europese Unie, het Verenigd Koninkrijk en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 0/6 |
| Toekomstige groei | 1/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
ORX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Orexo AB (publ) Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | SEK 19.42 |
| 52 Week Hoogtepunt | SEK 43.40 |
| 52 Week Laag | SEK 16.00 |
| Bèta | 0.87 |
| 1 maand verandering | 4.41% |
| 3 maanden verandering | -25.16% |
| 1 Jaar Verandering | 18.41% |
| 3 jaar verandering | 96.16% |
| 5 jaar verandering | -52.14% |
| Verandering sinds IPO | -78.42% |
Recent nieuws en updates
Narratiefupdate • May 30
ORX: Overdose Treatment Progress And Higher Margins Will Support Future Upside
Analysts now see Orexo's fair value at SEK29.0, down from SEK38. This reflects updated assumptions for revenue growth, profit margins and a higher future P/E, alongside a modest increase in the discount rate.Narratiefupdate • Apr 25
ORX: Higher Profit Margins And Lower P/E Assumptions Will Support Future Upside
Analysts have adjusted their view on Orexo with a modest shift in price expectations in SEK terms, citing slightly higher projected profit margins at 19.52% and a lower assumed future P/E of 124.01x as key factors behind the new price target. Valuation Changes Fair Value: SEK 38.0 remains unchanged compared with the previous SEK 38.Narratiefupdate • Apr 09
ORX: Steady Margins And Elevated P/E Multiple Will Support Future Upside Potential
Analysts have kept their SEK price target for Orexo broadly steady, with only a marginal adjustment that reflects slightly revised views on long term profit margins and the future P/E multiple, while leaving fair value, discount rate, and revenue growth assumptions effectively unchanged. Valuation Changes Fair Value: SEK 38.0 per share, effectively unchanged from the previous SEK 38.Recent updates
Narratiefupdate • May 30
ORX: Overdose Treatment Progress And Higher Margins Will Support Future Upside
Analysts now see Orexo's fair value at SEK29.0, down from SEK38. This reflects updated assumptions for revenue growth, profit margins and a higher future P/E, alongside a modest increase in the discount rate.Narratiefupdate • Apr 25
ORX: Higher Profit Margins And Lower P/E Assumptions Will Support Future Upside
Analysts have adjusted their view on Orexo with a modest shift in price expectations in SEK terms, citing slightly higher projected profit margins at 19.52% and a lower assumed future P/E of 124.01x as key factors behind the new price target. Valuation Changes Fair Value: SEK 38.0 remains unchanged compared with the previous SEK 38.Narratiefupdate • Apr 09
ORX: Steady Margins And Elevated P/E Multiple Will Support Future Upside Potential
Analysts have kept their SEK price target for Orexo broadly steady, with only a marginal adjustment that reflects slightly revised views on long term profit margins and the future P/E multiple, while leaving fair value, discount rate, and revenue growth assumptions effectively unchanged. Valuation Changes Fair Value: SEK 38.0 per share, effectively unchanged from the previous SEK 38.Narratiefupdate • Mar 26
ORX: Stable Margins And High P/E Multiple Will Support Upside Potential
Analysts have kept their SEK fair value estimate for Orexo broadly unchanged at SEK38.0, reflecting only minor tweaks to long term margin and P/E assumptions rather than any shift in the core thesis. Valuation Changes Fair Value: SEK38.0 remains essentially unchanged compared with the prior SEK38 estimate.Narratiefupdate • Mar 12
ORX: Future P/E Support Will Rely On Stable Margins
Analysts have kept their SEK fair value estimate for Orexo broadly unchanged at SEK 38.0. This reflects only minor tweaks to underlying assumptions, such as slightly higher modeled revenue growth and a marginally lower future P/E multiple. Valuation Changes Fair Value: SEK 38.0 per share, unchanged from the prior SEK 38 estimate.Narratiefupdate • Feb 25
ORX: Future P E Multiple Will Rely On Sustained Margin Support
Analysts have raised their price target for Orexo to SEK 38, citing an assumed revenue growth rate of 35% and a projected future P/E of about 129, while forecast profit margins are expected to ease to around 19%. Valuation Changes Fair Value: SEK 38 is unchanged, with the updated estimate remaining at SEK 38.0. Discount Rate: 5.224% is unchanged between the previous and updated assumptions.Narratiefupdate • Feb 06
ORX: Higher Required Return Will Still Support Very Large Future P E Multiple
Narrative Update Analysts have trimmed their price target on Orexo to US$38.00, reflecting slightly higher discount rate assumptions and a modestly lower profit margin outlook. They are still applying a very large forward P/E multiple that keeps the fair value estimate unchanged at US$38.00.Narratiefupdate • Jan 22
ORX: Stable Assumptions And Elevated P/E Will Support Long Term Upside
Analysts have kept their fair value target for Orexo unchanged at $38.00, citing largely stable assumptions around the discount rate, revenue expectations, profit margin, and a very high forward P/E estimate. Valuation Changes Fair Value: Kept unchanged at SEK 38.00 per share, reflecting stable core assumptions.Narratiefupdate • Jan 07
ORX: Revised Earnings Assumptions Will Shape Balanced Long Term Prospects
Analysts have raised their price target on Orexo from SEK 31 to SEK 38, citing a substantial revision to future P/E assumptions and significantly lower revenue growth expectations, while keeping profit margin and discount rate inputs broadly unchanged. Valuation Changes Fair Value Target: raised from SEK 31 to SEK 38, reflecting a higher indicated equity value per share.Narratiefupdate • Dec 14
ORX: New Science Park Facilities Will Support Stronger Long Term Prospects
Analysts have modestly raised their price target on Orexo to $31.00, highlighting a slightly richer future earnings multiple that is expected to offset a small anticipated erosion in long term profit margins. What's in the News Relocating to new, modern premises in Uppsala Science Park to support the next phase of the company’s development and growth (Key Developments) New facilities include laboratories, cleanrooms, and flexible office spaces designed to strengthen research and development capabilities (Key Developments) Site designed with a clear sustainability profile, featuring energy and cost efficient solutions to reduce environmental impact (Key Developments) Move aims to foster greater collaboration and innovation with partners, academia, healthcare providers, and patients (Key Developments) Valuation Changes Fair Value: Unchanged at SEK 31.0 per share, indicating no revision to the central valuation estimate.Narratiefupdate • Nov 28
ORX: New Facility Move And R&D Will Drive Future Performance
Analysts have updated their price target for Orexo to $31.00. They are maintaining their previous estimate, as underlying assumptions around revenue growth and discount rates remain largely unchanged.Narratiefupdate • Nov 13
ORX: Future Profit Margin Gains And R&D Move To Support Outlook
Narrative Update on Orexo Analysts have maintained their fair value estimate for Orexo at $31.00, citing stable expectations for revenue growth and recent improvements in profit margin projections as key factors supporting their unchanged price target. What's in the News Orexo AB is relocating to modern premises in Uppsala Science Park to strengthen research and development, enhance collaboration, and promote sustainability within its operations (Key Developments).Analyseartikel • Nov 02
Why Investors Shouldn't Be Surprised By Orexo AB (publ)'s (STO:ORX) 28% Share Price Plunge
Orexo AB (publ) ( STO:ORX ) shares have retraced a considerable 28% in the last month, reversing a fair amount of their...Narratiefupdate • Oct 30
ORX: Relocation And In-Vivo Results Will Support Measured Opportunity Ahead
Analysts have raised their price target for Orexo to $31.00 per share. This update reflects improving revenue growth forecasts and a slightly higher projected profit margin.Narratiefupdate • Oct 16
Zubsolv Litigation Settlement And OX640 Progress Will Secure Stability
Analysts have raised their price target for Orexo from $21.50 to $31.00. This decision is based on updated valuation methodologies, even as growth and margin expectations have been slightly adjusted.Analyseartikel • Sep 16
There's No Escaping Orexo AB (publ)'s (STO:ORX) Muted Revenues Despite A 29% Share Price Rise
Orexo AB (publ) ( STO:ORX ) shareholders have had their patience rewarded with a 29% share price jump in the last...Analyseartikel • Jun 10
Orexo AB (publ) (STO:ORX) Shares Fly 32% But Investors Aren't Buying For Growth
Orexo AB (publ) ( STO:ORX ) shareholders have had their patience rewarded with a 32% share price jump in the last...Analyseartikel • May 09
Orexo AB (publ) (STO:ORX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Orexo AB (publ) ( STO:ORX ) investors will be delighted, with the company turning in some strong numbers with its...Analyseartikel • May 02
Shareholders May Not Be So Generous With Orexo AB (publ)'s (STO:ORX) CEO Compensation And Here's Why
Key Insights Orexo to hold its Annual General Meeting on 8th of May CEO Nikolaj Sorensen's total compensation includes...
Nieuw narratief • Apr 10
Zubsolv Litigation Settlement And OX640 Progress Will Secure Stability
Legal settlements and strategic changes stabilize revenue streams, enhancing future planning and financial clarity for Orexo.Analyseartikel • Dec 20
A Piece Of The Puzzle Missing From Orexo AB (publ)'s (STO:ORX) 105% Share Price Climb
Orexo AB (publ) ( STO:ORX ) shareholders would be excited to see that the share price has had a great month, posting a...Analyseartikel • Nov 05
Orexo AB (publ) (STO:ORX) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
The Orexo AB (publ) ( STO:ORX ) share price has fared very poorly over the last month, falling by a substantial 26...Analyseartikel • Aug 02
Orexo AB (publ) (STO:ORX) Might Not Be As Mispriced As It Looks After Plunging 28%
Orexo AB (publ) ( STO:ORX ) shareholders won't be pleased to see that the share price has had a very rough month...Analyseartikel • Jul 20
Orexo AB (publ) (STO:ORX) Just Reported Earnings, And Analysts Cut Their Target Price
The analyst might have been a bit too bullish on Orexo AB (publ) ( STO:ORX ), given that the company fell short of...Analyseartikel • May 29
Orexo AB (publ) (STO:ORX) Soars 28% But It's A Story Of Risk Vs Reward
Despite an already strong run, Orexo AB (publ) ( STO:ORX ) shares have been powering on, with a gain of 28% in the last...Analyseartikel • Apr 03
Orexo AB (publ)'s (STO:ORX) Business And Shares Still Trailing The Industry
Orexo AB (publ)'s ( STO:ORX ) price-to-sales (or "P/S") ratio of 0.9x might make it look like a strong buy right now...Analyseartikel • Dec 09
We Think Orexo (STO:ORX) Has A Fair Chunk Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Rendement voor aandeelhouders
| ORX | SE Pharmaceuticals | SE Markt | |
|---|---|---|---|
| 7D | -10.5% | -2.0% | -1.4% |
| 1Y | 18.4% | -24.5% | 11.5% |
Rendement versus industrie: ORX overtrof de Swedish Pharmaceuticals industrie, die het afgelopen jaar een rendement -24.5 % opleverde.
Rendement versus markt: ORX overtrof de Swedish markt, die het afgelopen jaar een rendement opleverde van 11.5 %.
Prijsvolatiliteit
| ORX volatility | |
|---|---|
| ORX Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 13.8% |
| 10% least volatile stocks in SE Market | 3.7% |
Stabiele aandelenkoers: ORX heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de Swedish markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van ORX is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1994 | 65 | Nikolaj Sorensen | www.orexo.com |
Orexo AB (publ), een farmaceutisch bedrijf, ontwikkelt en commercialiseert geneesmiddelen en digitale therapieën in de Verenigde Staten, de Europese Unie, het Verenigd Koninkrijk en internationaal. Tot haar producten behoren Zubsolv tabletten voor de behandeling van opioïde gebruiksstoornissen; Abstral voor de behandeling van doorbraakpijn bij kankerpatiënten; en Edluar voor de behandeling van slapeloosheid. Het bedrijf ontwikkelt OX124 voor de behandeling van een overdosis opioïden; OX125 voor reddingsmedicatie en overdosis opioïden; OX640 voor de behandeling van anafylaxie met epinefrine in poedervorm; en OX-MPI voor de behandeling van endometriose.
Orexo AB (publ) Samenvatting
| ORX fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | SEK 678.18m |
| Inkomsten(TTM) | -SEK 417.90m |
| Inkomsten(TTM) | SEK 17.80m |
38.1x
P/S-verhouding-1.6x
Koers/WinstverhoudingIs ORX overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ORX resultatenrekening (TTM) | |
|---|---|
| Inkomsten | SEK 17.80m |
| Kosten van inkomsten | SEK 10.30m |
| Brutowinst | SEK 7.50m |
| Overige uitgaven | SEK 425.40m |
| Inkomsten | -SEK 417.90m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
Jul 16, 2026
| Winst per aandeel (EPS) | -11.97 |
| Brutomarge | 42.13% |
| Nettowinstmarge | -2,347.75% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde ORX op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/03 16:34 |
| Aandelenkoers aan het einde van de dag | 2026/06/03 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Orexo AB (publ) wordt gevolgd door 8 analisten. 1 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| null null | ABG Sundal Collier |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Mattias Häggblom | Danske Bank |